Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial

1. Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524-33. doi:10.1016/S2352-3026(21)00105-8.

2. Barrett TJ, Cornwell M, Myndzar K, et al. Platelets amplify endotheliopathy in COVID-19. Sci Adv. 2021;7(37):eabh2434. doi:10.1126/sciadv.abh2434.

3. Martha JW, Pranata R, Lim MA, et al. Active prescription of lowdose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis. 2021;108:6-12. doi:10.1016/j.ijid.2021.05.016.

4. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. Lancet. 2022;399(10320):143-151. doi:10.1016/S0140-6736(21)01825-0.

5. Berger JS, Kornblith LZ, Gong MN, et al., for the ACTIV-4a Investigators. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19. A Randomized Clinical Trial. JAMA. 2022;327:227-36. doi:10.1001/jama.2021.23605.